SecBot SecBot

HALO

HALOZYME THERAPEUTICS, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001159036 Biotech & Drug Discovery
$96.50 −3.77 (−3.76%)
Nov 16 4:00 PM ET · prev $100.27
Market cap
$11.5B
Large cap
Consensus
Buy
81% Buy or better · 16 analysts
Median target
$125.00
+30% · range $79.00–149.00
1 year
+36.8%
from $70.56 · Nov 17
30 days
−21.2%
from $122.50
52-week range
$61.63–131.18
−26% from high · low Mar 27
Avg volume 20D
2.37M
Nov 6 spike 6.16M
Short interest
13.65M
≈12.0% of shares · −0.0%
Days to cover
6.8
at average volume
Insider net
−$15.7M
since Sep 1 · excl. 10 subscriber-only trades
New fund stakes
4
Q3 2026 13F · 3 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 10 reports · 90 days
Balance 3 bearish · 3 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 9/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    2 insiders sold $15.7M. Excludes 10 subscriber-only trades.

  • InstitutionsBULLISH

    Q3 2026: 55 added (4 new), 35 trimmed or exited. Largest new: Wasatch Advisors $115.9M, Qube Research & Technologies $13.4M.

  • AnalystsBULLISH

    13 of 16 rate it Buy or better. Median target $125.00 (+30%).

  • Short sellersSTEADY

    Short interest −0.0% to 13.65M shares. 6.8 days to cover, ≈12.0% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 23.

Who's buying

13F· Q3 2026
4
new positions
3
exits
$140.5M
in new stakes · top 3 shown
FundMoveSharesValue
CONGRESS ASSET MANAGEMENT COADD2,281,615$251.9M
FIRST TRUST ADVISORS LPADD1,817,824$200.7M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCTRIM1,616,472$178.5M
JANE STREET GROUP, LLCDOUBLED1,518,683$167.7M
ROYAL LONDON ASSET MANAGEMENT LTDTRIM1,250,564$138.1M
Neuberger Berman Group LLCDOUBLED1,206,919$133.2M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPTRIM1,161,257$128.2M
WASATCH ADVISORS LPNEW1,049,647$115.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 81% rate it Buy or better
Strong Buy3Buy10Hold3Sell0Strong Sell0
12-month targets · 9 analysts

Price is inside the target range. Median implies +30%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Morgan Stanley
DOWNGRADE
DOWNGRADEEqual-Weight
Nov 6, 2026Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform
Nov 6, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Nov 6, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Nov 6, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Nov 3, 2026JP Morgan
MAINTAIN
MAINTAINNeutral

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$15.7M
sold · 2 insiders · excl. 10 subscriber-only trades
DateInsiderTypeValue
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
EXERCISE
Nov 16, 2026🔒 Fresh data, subscribers only
Nov 16, 2026
SELL
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
SELL

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$2.33$2.32–$2.34-0.4%$488.7M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
13,650,219
shares short
-0.0%
vs prior settlement
6.8
days to cover
≈12.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
7 drugs tracked · Drug pipeline →
Recent
Nov 9, 2026
Ptab trial
PTAB PGR2025-00042: Final written decision, U.S. Patent 12037618 (Halozyme, Inc. v. Merck Sharp & Dohme LLC)
Patent: PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
Nov 6, 2026
Press release
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company…
Nov 6, 2026
FDA
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme…
Nov 5, 2026
Earnings result
HALO Q3 2026 Earnings: EPS $2.39 (-0.3% vs est)
Oct 22, 2026
Earnings
Halozyme to Report Third Quarter 2026 Financial and Operating Results
SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter…
Congressional trades
HALO trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 1 sells
DateMemberType AmountDisclosed
Sep 29, 2026 Gilbert CisnerosDHouse Halozyme Therapeutics Inc SELL $1K–$15K Oct 12, 2026 +13d
Mar 9, 2026 Gilbert CisnerosDHouse Halozyme Therapeutics Inc BUY $1K–$15K Apr 7, 2026 +29d

SecBot reports

14 filings · 1 press release · 2 bullish · 3 bearish · 1 mixed · 8 neutral
All HALO filing & press-release reports (15)